The Barcelona-based firm, which has a protein splicing platform that aims to address the major limitation of delivering large genes using AAV vectors, has sealed the largest series A fundraising by a Spanish biotech.

Confirming rumors of an acquisition, CSL will venture into some new territories as well as boost its renal franchise when it takes over Switzerland’s Vifor Pharma in a deal worth $11.7bn.

After investing more than €23m in Sanifit, the Spanish firm being acquired by Vifor Pharma, Caixa Capital's director of life sciences investments spoke to Scrip about the venture capital firm's long-term approach.

A couple of months after licensing the late-stage kidney disease drug sparsentan from Travere, the Swiss group has beefed up its nephrology activities by buying Mallorca-based Sanifit and Swiss outfit Inositec.